Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
enfortumab vedotin + carboplatin
- Development stage
- Preclinical
- Lead developer
- Astellas Pharma
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Enfortumab vedotin + carboplatin is a combination regimen of two agents: **enfortumab vedotin**, an antibody-drug conjugate that targets Nectin-4 with a cytotoxic payload of monomethyl auristatin E (MMAE), and **carboplatin**, a platinum-based chemotherapeutic. Enfortumab vedotin delivers MMAE to Nectin-4–expressing cancer cells, leading to microtubule disruption, cell cycle arrest, and apoptosis. Carboplatin causes DNA crosslinking and apoptosis by forming platinum-DNA adducts. This combination is primarily under clinical investigation for the treatment of advanced or metastatic urothelial carcinoma in patients unable to receive cisplatin or immunotherapy.
- Other names
- enfortumab vedotin plus carboplatin
02
Targets
PVRL4 (Nectin cell adhesion molecule 4)DNATUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on enfortumab vedotin + carboplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on enfortumab vedotin + carboplatin.